OlympiA
Adjuvant Olaparib for High-Risk gBRCA-Mutant Early Breast Cancer
Doente / População Intervenção / Exposição Comparação Desfecho
In 1,836 patients with HER2-negative, high-risk early breast cancer and germline BRCA1/2 mutation, one year of adjuvant olaparib reduced invasive disease-free survival events compared with placebo.
N
1836
Desenho
Double-blind RCT
Desfecho
Invasive disease-free survival
Relevância
2
Resultado3-yr iDFS 85.9% vs 77.1% (HR 0.58). 4-yr OS 89.8% vs 86.4% (HR 0.68).
Tutt ANJ, et al. N Engl J Med. 2021;384(25):2394-2405. 10.1056/NEJMoa2105215
Discussão e crítica
First positive PARP-inhibitor trial in (neo)adjuvant breast cancer. Requires upfront germline BRCA testing, including in early-stage disease.